Brands
Lush rolls out winter line-up with ethical hair, skin and bodycare
BENGALURU: British cosmetics brand Lush has unveiled its winter line-up in India, rolling out a curated range of haircare, skincare and bath and body products aimed at repairing and nourishing skin and hair through the colder months. The collection is now available on Lush.in.
Staying true to the brand’s ethos, the seasonal assortment is handmade using fresh ingredients, responsibly sourced essential oils and aromatherapy-led formulations. The winter edit underscores Lush’s long-standing commitment to cruelty-free, ethical beauty, combining indulgent textures with functional, plant-powered performance.
Bilberry Brands founder and CEO Vishal Anand, the exclusive licensee partner for Lush in India, said the winter range reflects the brand’s focus on simple, effective recipes rooted in ethical sourcing and craftsmanship. He added that ingredients such as Turkish rose absolute, Sicilian lemon and vitamin-rich botanical oils are designed to protect and nourish skin and hair during colder weather.
The line-up features several global bestsellers. Wasabi Shan Kui shampoo, priced at Rs.1,795, returns as a winter hero for dull hair, formulated with wasabi, horseradish purée and fresh lemon juice to boost scalp circulation and shine. Super Milk conditioning spray, retailing at Rs.2,495 and selling at a rate of one bottle every 40 seconds globally, offers lightweight leave-in conditioning with almond, coconut and oat milks.
For textured hair, Glory conditioner (Rs.1,595) blends coconut cream, okra gel and castor oil to combat winter dryness, while Daddy-O shampoo (Rs.1,495) uses violet pigments and citrus oils to keep blonde and greying hair bright. Happy Happy Joy Joy conditioner (Rs.1,895) combines rose water from Turkey and Tunisian neroli for hydration with a lingering floral finish.
In skincare, Celestial moisturiser (Rs.3,995), a Lush bestseller since 1996, returns in a self-preserving formula designed to soothe sensitive winter skin, while Eau Roma Water toner (Rs.1,395) offers a minimalist blend of lavender and rose waters to calm irritation. Bath and body highlights include Ro’s Argan in-shower moisturiser (Rs.1,095) and the Rose Jam shower gel (Rs.1,695), both infused with Fair Trade cocoa butter, argan oil and Turkish rose absolute.
Lush said all products in the winter collection are made using ethically sourced ingredients, from vanilla grown by smallholder farmers in Uganda and Tanzania to neroli from family-run producers in Tunisia.
Brands
Sun Pharma to acquire Organon in $11.75 billion deal at $14 per share
Acquisition to create $12.4 billion pharma giant with global scale and biosimilars push
MUMBAI: Sun Pharmaceutical Industries Limited has signed a definitive agreement to acquire Organon & Co. in an all-cash deal valued at $11.75 billion, marking one of the largest cross-border pharma acquisitions by an Indian firm.
Under the terms of the agreement, Organon shareholders will receive $14.00 per share in cash, with Sun Pharma set to acquire 100 per cent of the company’s outstanding shares. The transaction, approved by the boards of both companies, is expected to close in early 2027, subject to regulatory approvals and shareholder consent.
The deal significantly expands Sun Pharma’s global footprint and strengthens its position across women’s health, biosimilars, and branded generics. The combined entity is projected to generate revenues of around $12.4 billion, placing it among the top 25 pharmaceutical companies globally.
Organon, which was spun off from Merck in 2021, brings a portfolio of over 70 products spanning women’s health and general medicines, with operations across more than 140 countries. Its established presence in key markets such as the US, Europe, and China complements Sun Pharma’s existing strengths and growth ambitions.
Sun Pharmaceutical Industries Limited executive chairman Dilip Shanghvi said, “This transaction represents a significant opportunity for Sun Pharma to build on its vision of reaching people and touching lives. Organon’s portfolio, capabilities and global reach are highly complementary to our own.”
Sun Pharmaceutical Industries Limited managing director Kirti Ganorkar added, “This transaction is a logical next step in strengthening Sun Pharma’s global business. Together, we will become a partner of choice for acquiring and launching new products.”
From Organon’s side, Organon & Co. executive chair Carrie Cox noted, “This all-cash transaction offers compelling and immediate value to Organon stockholders, while positioning the business for continued growth under Sun Pharma.”
Strategically, the acquisition gives Sun Pharma entry into the global biosimilars space as a top 10 player and strengthens its innovative medicines portfolio, which is expected to contribute around 27 per cent of combined revenues. The deal is also expected to nearly double EBITDA and cash flow, supporting long-term deleveraging and investment capacity.
Sun Pharma plans to fund the acquisition through a mix of internal accruals and committed financing from global banks, while maintaining focus on disciplined integration and operational continuity post-merger.
If completed as planned, the deal signals a clear shift in India’s pharmaceutical ambitions, from scale at home to leadership on the global stage, with Sun Pharma positioning itself as a more diversified and innovation-led healthcare powerhouse.
